Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BMBristol-Myers Squibb Company logo

Bristol-Myers Squibb Company (BMY)

New York Stock Exchange · Currency in USD
$61.48 ▼ -1.52 (-2.41%)
At close: Oct 23, 4:00 PM ET. Market closed.
$62.01 ▲ +0.53 (+0.86%)
After hours: Oct 23, 5:03 PM ET

Summary

Previous Close
$63.00
Open
$62.66
Day's Range
$61.31 – $62.84
52 Week Range
$42.52 – $68.64
Volume
9,762,437
Avg. Volume
11,991,091
Market Cap
$125.59B
Beta (5Y Monthly)
0.23
PE Ratio (TTM)
13.54
EPS (TTM)
$4.55
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
$2.52 (4.10%)
Ex-Dividend Date
Oct 2, 2026
1y Target Est
$66.08

Profile: Bristol-Myers Squibb Company

Sector
Healthcare
Industry
Drug Manufacturers - General
Full-time employees
32,500
CEO
Christopher Boerner
Website
bms.com

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate $1.10 · Revenue est. $12.73B
DateEst.Actual
Jul 30, 2026$1.60$2.04Beat
Apr 30, 2026$1.42$1.58Beat
Feb 5, 2026$1.23$1.26Beat
Oct 30, 2025$1.52$1.63Beat
Jul 31, 2025$1.09$1.46Beat
Apr 24, 2025$1.49$1.80Beat

Analyst view

Consensus price target
$66.08 ▲ +7.5%
Range $41.00 – $82.00
Rating: Hold
Buy 45% · Hold 50% · Sell 5%

Get free alerts on BMY and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.